

Final preparation for Phase 2 - SpectraCure extends contract with hospital in London

Prior to the upcoming Phase 2 study, SpectraCure has today extended the agreement with University College London Hospital (UCL) for two years. The agreement is intended to cover the entire phase 2 for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. The purpose of the Phase 2 study is continued evaluation of safety and clinical benefit of PDT treatment of prostate cancer according to SpectraCure's clinical program.

As planned, the contract terms and costs for phase 2 are essentially unchanged compared to the contract terms that have applied to the successful phase 1 study. As before, this means a part with a fixed cost per calendar year, as well as a variable part for each patient who is treated in the clinical study. The funding is covered by the Preferential rights issue made in November 2018.

This was the last agreement that needed to be signed prior to the Phase 2 study. The agreements previously signed with the other study hospitals, the Princess Margaret Cancer Centre in Toronto, and the University of Pennsylvania Hospital in Philadelphia, already include the Phase 2 study.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region